Ingredient or product comparison
AHK-Cu for Alopecia Areata: Treatment Comparison
AHK-Cu (topical) Wnt/β-catenin activation, follicular stem cell proliferation, ECM repair 8–16 weeks for visible terminal hair regrowth Moderate (30–40%). Structural changes may persist longer than immune suppression effects Best for refractory cases where inf
This source-based comparison does not add ratings or recommend a winner.
- AHK-Cu (topical)
- Wnt/β-catenin activation, follicular stem cell proliferation, ECM repair
- 8–16 weeks for visible terminal hair regrowth
- Moderate (30–40%). Structural changes may persist longer than immune suppression effects
- Best for refractory cases where inflammation is controlled but regrowth stalled; combines well with JAK inhibitors or corticosteroids
- Intralesional corticosteroids (triamcinolone)
- Immune suppression (T cell inhibition at follicle site)
- 4–8 weeks for initial regrowth
- High (50–70%). Does not repair stem cell niche damage
- First-line for localised patches; limited efficacy in chronic or extensive alopecia areata
- JAK inhibitors (tofacitinib, baricitinib)
- Cytokine signaling blockade (IFN-γ, IL-15)
- 2–6 months for significant coverage
- Very high (60–80%) within 6 months of stopping
- Most effective for severe or totalis cases; high cost and relapse risk limit long-term viability as monotherapy
- Minoxidil (topical)
- Vasodilation, anagen prolongation via KATP channel activation
- 12–24 weeks (slow onset in alopecia areata)
- Moderate (40–50%). Effect is maintenance-dependent
- Minimal standalone efficacy for alopecia areata but useful adjunct to immune-modulating or peptide-based protocols
- Anthralin (contact immunotherapy)
- Induced allergic dermatitis redirects immune response away from follicle
- 12–20 weeks
- Moderate (35–50%)
- Effective for extensive disease but requires dermatologist supervision; irritation limits tolerability